Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Argus Health
Accenture
Colorcon
AstraZeneca
Julphar
Healthtrust
US Department of Justice
Queensland Health

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: RE41134

« Back to Dashboard

Summary for Patent: RE41134
Title:Slow release vehicles for minimizing skin irritancy of topical compositions
Abstract:.[.Staple.]. .Iadd.Stable.Iaddend., aqueous gel vehicles are provided for the topical application to the skin of irritating active ingredients such as retinoids, particularly tretinoin, with slow release of the active ingredient and minimal irritancy to the skin. The vehicles include a gelling agent effective to form a gel and hold the active ingredient in the aqueous medium for slow release on the skin, and an effective amount of an antioxidant to retard decomposition of the active ingredient. The vehicles and formulations are preferably aqueous emulsions which contain a solubilizing agent for the generally non-water soluble active ingredients, as well as usually an emulsifying agent and/or surfactant. Chelating agents, emollients, preservatives and other adjuvants and additives may also be included in the vehicles and formulations.
Inventor(s): Bazzano; Gail S. (Metairie, LA)
Assignee: Alyzan, Inc. (Metairie, LA)
Application Number:10/999,235
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE41134
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent RE41134

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE41134

PCT Information
PCT FiledJune 07, 1999PCT Application Number:PCT/US90/03219
PCT Publication Date:December 13, 1990PCT Publication Number: WO90/14833

International Family Members for US Patent RE41134

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2063576 ➤ Sign Up
Germany 69029804 ➤ Sign Up
European Patent Office 0481007 ➤ Sign Up
World Intellectual Property Organization (WIPO) 9014833 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Mallinckrodt
Accenture
Teva
Daiichi Sankyo
Deloitte
Fish and Richardson
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.